Navigation Links
Reportlinker Adds Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion
Date:1/11/2011

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

http://www.reportlinker.com/p0360249/Forecast-Insight-Antihypertensives---Fixed-dose-combinations-fail-to-offset-generic-erosion.html

IntroductionAs branded angiotensin receptor blockers (ARBs) lose market exclusivity, fixed-dose combinations become the only remaining products able to generate growth in the antihypertensives market. However, they will not be able to do enough to prevent market erosion which will fall from $37.5 billion in 2009 to $28.6 billion in 2019 at -3% CAGR.

Features and benefits

* Analysis of revenue and volume sales of antihypertensive drug classes in the seven major markets* Assess the impact of key patent expiries, such as Merck & Co's Cozaar and Hyzaar* Forecast antihypertensive revenue and volume sales to 2019, including performance of developmental agents* Understand the impact of clinical trials and pipeline agents on future market dynamics

HighlightsThe first triple drug combination; Exforge HCT (valsartan + amlodipine + hydrochlorothiazide) has reached the US market. Valturna (aliskiren + valsartan; Novartis) has combined the direct renin inhibitor aliskiren with the ARB valsartan to become the first drug to offer dual blockade of the renin angiotensin system.The only innovative antihypertensive agent expected to launch by 2019 is Takeda's ARB; azilsartan medoxomil (TAK-491). Launching in this time frame will make azilsartan an extremely late entry to the ARB class and the drug is going to experience of number of resistors to success.Japan has seen a number of recent launches of ARB combinations. If the new launches replicate the success of Hyzaar (launched in 2006) and Japanese physicians accept the ARB + CCB (calcium channel blocker) combination this will represent the strongest opportunity for class growth in the seven major markets.

Your key questions answered* Quantify and qualify antihypertensive sales in each of the seven major markets for 2006–2019* Examine the future performance of leading antihypertensive brands and how the growth of generics will impact revenues* Understand challenges faced by pipeline agents and new fixed-dose-combinations

To order this report:: Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... global chromatography market to grow at a CAGR of 5.42% during the ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/8/2016)... 8, 2016  Economic growth in the United States ... supply management executives in their December 2016 Semiannual Economic ... recovery that began in mid-2009, as indicated in the ... ® . The manufacturing sector is optimistic about growth ... manufacturing industries, and the non-manufacturing sector indicates that 14 ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... Birmingham, AL (PRWEB) , ... December 08, 2016 ... ... insurance and financial planning services from offices headquartered in Jefferson County, is announcing ... Pathways Woman’s Shelter in Birmingham. , The number of homeless women and children ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... consulting services to residential and commercial clients in the northern Alabama and Georgia ... Nobis Works. , Since 1977, Nobis Works has built a network of support ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental health ... health systems reform legislation in more than fifty years. We applaud the bipartisan ... our elected officials to improving mental health services and supports in our nation. ...
Breaking Medicine News(10 mins):